Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
Taiho Oncology, Inc.
organization2 mentionslast seen Oct 2, 2026
A subsidiary of Taiho Pharmaceutical Co., Ltd. that specializes in the development and commercialization of orally administered anti-cancer agents.
Relationships 5
- Taiho Oncology, Inc.developszipalertinib99% confidence2 sources
- Taiho Pharmaceutical Co., Ltd.ownsTaiho Oncology, Inc.99% confidence2 sources
- Cullinan Therapeutics, Inc.partners withTaiho Oncology, Inc.99% confidence2 sources
- Taiho Oncology, Inc.employsHarold Keer95% confidence1 source
- Taiho Oncology, Inc.partners withTaiho Pharmaceutical Co., Ltd.95% confidence1 source
Relationship
Taiho Oncology, Inc.developszipalertinib
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGAROct 1, 2026Cullinan Therapeutics, Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Zipalertinib is being developed by Taiho Oncology, Inc., its parent company, Taiho Pharmaceutical Co., Ltd.
- filingSEC EDGARSep 14, 2026Cullinan Therapeutics, Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Zipalertinib is being developed by Taiho Oncology, Inc., its parent company, Taiho Pharmaceutical Co., Ltd., and in collaboration with Cullinan Therapeutics, Inc. in the U.S.